Marc Le Bozec
CEO & Director
Hello, everyone. I’m Marc Le Bozec. I’m the CEO of OSE Immunotherapeutics, a biotech company listed on Paris market. And we’re actually extremely pleased to welcome today, Stephen Liu, Benjamin Besse and Alexandra Leary to present some, first, the, let’s say, global vision on non-small cell lung cancer; second, a more precise approach on what our product, our lead product, Tedopi can bring to this disease; and eventually, Alexandra will present most recent data on ovarian cancer, which is a new indication for us that has been presented at ASCO very recently. Alexandra made an oral presentation at ASCO in Chicago a few days ago.
So in a few words, I would like to make a brief introduction on the company. This is a company I joined less than a year ago. And I’m absolutely convinced that this is a future — a great biotech company in France and in Europe because we have incredible products. We have this product that we will go into details today, which is Tedopi. It’s an immunotherapy, which is very promising with already more than 700 patients that have been treated. And we expect to have a Phase III readout early ’28. So it’s very close now. And we have a second compound, which is lusvertikimab, which has delivered a positive readout in inflammatory bowel disease last year, in particular, in ulcerative colitis. We are not going to elaborate on lusvertikimab today. This is not the purpose of this webinar.
So just if we can share, Thibault, the first slide to